Optimize Rheumatology Biologics Prior Auth Workflows

The High Burden of Rheumatology Biologics Prior Authorization

Rheumatology prior authorization is heavily concentrated in high-cost biologic and targeted therapies for conditions like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). These agents, including TNF-alpha inhibitors, IL-6/17/23 inhibitors, and JAK inhibitors, require rigorous documentation and often face complex step therapy and biosimilar substitution requirements. The chronic nature of these treatments means ongoing PA burden with frequent re-authorizations.

Navigating Specific Documentation for Rheumatology Biologics

• Diagnosis Documentation: ICD-10 codes with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA, ASAS for AS, 2019 EULAR/ACR for SLE).
• Disease Activity Assessment: Objective scores like DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE.
• Prior Conventional DMARD Trial: Documentation of methotrexate, sulfasalazine, or other csDMARD trial and response, or contraindication.
• Step Therapy Compliance: Evidence of failure or contraindication to required prior agents, including specific TNF inhibitors or biosimilars.
• Screening Completion: Documentation of TB (PPD or IGRA), hepatitis B/C, and immunization status prior to immunosuppressive biologic initiation.

Common Prior Authorization Denial Reasons in Rheumatology

Denials for rheumatology biologics frequently stem from non-compliance with payer-specific step therapy protocols or incomplete clinical documentation. This includes failure to demonstrate required prior agent trials, lack of objective disease activity scores, or missing critical pre-treatment screenings for immunosuppressive therapies. Klivira's platform is designed to preempt these common denial triggers.

Addressing Unique Operational Challenges in Rheumatology PA

• Chronic Treatment Re-authorization: Periodic (e.g., 6 or 12-month) re-authorization cycles requiring continuous documentation of disease response.
• Biosimilar Substitution Variability: Non-uniform payer policies on mandatory biosimilar substitution for specific TNF inhibitors and other biologics.
• Medical vs. Pharmacy Benefit Split: Same biologic agents may route through different benefit channels based on administration (self-administered vs. provider-administered infusion).
• Complex Step Therapy Interactions: Payer policies dictating specific biosimilars or sequences within step therapy, not just general drug classes.
• Pediatric Rheumatology Nuances: Additional complexity for pediatric patients due to weight-based dosing and specific guideline criteria.

Klivira's Solution for Rheumatology Biologics Prior Auth

Klivira's platform automates the intricate process of rheumatology biologics prior authorization by integrating directly with your EMR and connecting to payer portals. Our system leverages ACR-guideline-aware policy logic, manages biosimilar substitution routing, and streamlines periodic re-authorization workflows to ensure compliance and reduce manual effort.

How Klivira Streamlines Your Biologics PA Process

• Indication-Aware Policy Logic: Applies ACR-guideline-aware step therapy sequencing based on diagnosis and disease state.
• Automated Step Therapy Verification: Pulls prior-line therapy history (e.g., csDMARDs) from EMR data.
• Biosimilar Substitution Routing: Enforces per-payer biosimilar mandates, guiding appropriate drug selection.
• Screening Documentation Capture: Gathers required TB, hepatitis B/C, and immunization status from FHIR-enabled EMR data.
• Periodic Re-authorization Management: Proactively manages 6 or 12-month re-authorization cycles with required continuous response documentation.
• Benefit-Side Routing: Intelligently routes PA requests based on medical vs. pharmacy benefit for the same agent depending on administration.